Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

US Senators Call For Drug Pricing Inquest Into Opioid Overdose Antidote

XTALKS VITALS NEWS

Drug Pricing

The overdose antidote was first approved decades ago to treat patients who have taken an excess of opioid drugs, including heroin.

Share this!

June 8, 2016 | by Sarah Massey, M.Sc.

Amid growing concerns over opioid abuse and addiction, two US senators are asking drugmakers to explain their pricing for the opioid overdose drug, naloxone. The overdose antidote was first approved decades ago to treat patients who have taken an excess of opioid drugs, including heroin.

Tweet: The cost of #opioid overdose treatment continues to increase http://ctt.ec/Qfb1p+Despite calls from public officials to make opioid overdose treatment more affordable, the cost of treatment continues to increase. The number of overdose-related deaths has also risen over the past few years, with over 27,000 incidents recorded in 2014 in the US alone.

The two concerned senators – Maine Republican Susan Collins and Claire McCaskill, a Democrat from Missouri and chair of the Senate Special Committee on Aging – sent an identical letter to five pharmaceutical companies regarding recent price changes of the opioid antidote. According to the letters, the senators are concerned that increased prices for naloxone “may be limiting access for emergency responders and public health departments.”

McCaskill and Collins are not newcomers to the drug pricing debate. Both senators participated in highly-publicized hearings whereby representatives from Valeant Pharmaceuticals and Turing Pharmaceuticals – including then Turing CEO, Martin Shkreli – were questioned on their pharmaceutical pricing practices.



Naloxone is the senators’ newest target because of its effectiveness at limiting or even reversing the damaging effects of an overdose of prescription opioids or heroine on the brain. One of the main supplier of naloxone to hospitals, police departments and addiction recovery groups, Amphastar Pharmaceuticals, has been contacted regarding recent price hikes for the drug. In 2014, the company increased the list price of its 10-pack, pre-filled, 2-milliliter syringes from $120 to $330.

“It becomes critical in the field for a cop, a paramedic, or EMT worker,” said Dr. Lewis Nelson, an emergency medicine specialist at the New York University Langone Medical Center. “You could watch someone die without it.”

The price increase prompted Bernie Sanders and Representative Elijah Cummings to demand pricing information from Amphastar. In response, the company offered the opioid overdose medication to select states at a reduced price.

“One concern is that money for naloxone is coming out of the same pot as money for treatment and prevention,” said Alison Knopf, editor of Alcoholism & Drug Abuse Weekly. “The costlier it is, the less money for treatment and prevention.”


Keywords: Drug Pricing, Opioid, Overdose


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.